Halozyme Therapeutics Inc (HALO)

Financial leverage ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total assets	US$ in thousands	1,733,270	1,892,660	1,810,440	1,699,450	1,841,510	1,864,540	1,781,390	1,162,250	1,104,430	1,185,420	1,025,860	966,582	579,924	524,029	526,997	492,353	565,874	370,356	417,830	429,109
Total stockholders’ equity	US$ in thousands	83,808	249,181	151,033	65,850	169,798	96,991	293,171	260,256	196,953	281,674	119,746	67,595	151,047	98,988	105,577	58,042	91,765	245,353	260,052	260,047
Financial leverage ratio		20.68	7.60	11.99	25.81	10.85	19.22	6.08	4.47	5.61	4.21	8.57	14.30	3.84	5.29	4.99	8.48	6.17	1.51	1.61	1.65

December 31, 2023 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $1,733,270K ÷ $83,808K
= 20.68

The financial leverage ratio of Halozyme Therapeutics Inc. has shown significant fluctuations over the past eight quarters. This ratio measures the extent to which the company relies on debt financing rather than equity to fund its operations.

In Q4 2023, the financial leverage ratio was 20.68, indicating that the company had a higher level of debt relative to equity. This increase from the previous quarter suggests a potential increase in debt obligations relative to its equity base.

Comparing Q4 2022 and Q4 2023, there has been a substantial increase in the financial leverage ratio from 10.85 to 20.68, signifying an elevated reliance on debt to finance operations over this period.

Q2 2022 exhibited a relatively lower financial leverage ratio of 6.08, which indicates a more balanced mix of debt and equity in the company's capital structure. However, this ratio increased in subsequent quarters, peaking at 25.81 in Q1 2023, reflecting a heightened level of leverage at that point in time.

Overall, the fluctuating trend in the financial leverage ratio of Halozyme Therapeutics Inc. suggests varying levels of financial risk and the company's changing capital structure as it navigates different financing arrangements. Monitoring this ratio will be crucial to assess the company's ability to meet its debt obligations and sustain a healthy financial position.